Sign in

    Ross Osborne

    Research Analyst at Cantor Fitzgerald

    Ross Osborn is an Equity Research Analyst at Cantor Fitzgerald specializing in healthcare sector coverage, particularly medical technology and life sciences companies such as SI-BONE, Neuropace, MiMedx Group, Cerus, Pacific Biosciences, and AVITA Medical. Since joining Cantor Fitzgerald in late 2021 after a prior role as Research Associate at Stephens Inc., Osborn has issued over 230 stock price targets across 20 companies, with a price target met ratio of 30.9% and notable calls like an 8.97% gain on Neuropace achieved in a single day. His TipRanks profile indicates a coverage universe of 28 stocks, a success rate of approximately 24%, and mixed performance metrics, while AnaChart reports an average price target potential upside of 48.43% within 124 days. Osborn holds an undergraduate degree from Wake Forest University, covers firms primarily in healthcare, and began publishing public recommendations in 2021.

    Ross Osborne's questions to ELUTIA (ELUT) leadership

    Ross Osborne's questions to ELUTIA (ELUT) leadership • Q2 2025

    Question

    Speaking for Ross Osborne, Matt Park of Cantor Fitzgerald asked about the outlook for gross margin expansion and the clinical evidence strategy required for the FDA approval of the NXT 41X platform.

    Answer

    CFO Matt Ferguson stated that the company sees clear opportunities to expand gross margins through scaling Elupro production, growing the high-margin cardiovascular business, and improving efficiency in the SimpliDerm franchise. CEO Randy Mills added that the NXT 41X platform will follow the same combination device regulatory pathway as Elupro, which they are confident in navigating. He noted the staggered launch is a marketing strategy to build clinical data, not a regulatory necessity.

    Ask Fintool Equity Research AI